Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 12/20 | 0.49 |
| ▸ | CBLC | Q9ULV8 | 3/20 | 0.49 |
| ▸ | CBL | P22681 | 6/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578272 | 0.90 | CBLB (0.59) | CBLBCBLCCBL | |
| SCHEMBL31578230 | 0.90 | CBLB (0.48) | CBLBCBLCCBLNTRK1PDCD1 | |
| SCHEMBL31578110 | 0.88 | CBLB (0.48) | CBLBCBLCCBLPDCD1CD274 | |
| SCHEMBL25348900 | 0.87 | CBLB (0.40) | CBLBCBLCCBL | |
| SCHEMBL31578100 | 0.87 | CBLB (0.48) | CBLBCBLCCBLCYP1A2CYP3A4 | |
| SCHEMBL25349187 | 0.87 | CBLB (0.39) | CBLBCBLCCBL | |
| SCHEMBL31578306 | 0.87 | CBLB (0.40) | CBLBCBLCCBL | |
| SCHEMBL31578262 | 0.87 | CBLB (0.39) | CBLBCBLCCBL | |
| SCHEMBL31115377 | 0.85 | CBLB (0.45) | CBLBCBLCCBLNTRK1CYP1A2 | |
| SCHEMBL30521224 | 0.82 | CBLB (0.48) | CBLBCBLCCBL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | NFATC1, GZMB, IFNG | CBLB 2362/4885CBLC 2283/4885CBL 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.